Free Trial

Mereo BioPharma Group (MREO) Stock Price, News & Analysis

+0.27 (+9.15%)
(As of 03:16 PM ET)
Today's Range
50-Day Range
52-Week Range
2.35 million shs
Average Volume
1.41 million shs
Market Capitalization
$451.64 million
P/E Ratio
Dividend Yield
Price Target

Mereo BioPharma Group MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
101.2% Upside
$6.50 Price Target
Short Interest
1.58% of Shares Sold Short
Dividend Strength
News Sentiment
0.58mentions of Mereo BioPharma Group in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$298,283 Sold Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.82 out of 5 stars

Medical Sector

590th out of 931 stocks

Pharmaceutical Preparations Industry

263rd out of 433 stocks

MREO stock logo

About Mereo BioPharma Group Stock (NASDAQ:MREO)

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

MREO Stock Price History

MREO Stock News Headlines

MREO Apr 2024 3.500 put
MREO Aug 2024 5.500 call
MREO Apr 2024 1.500 call
MREO Apr 2024 3.000 put
Voyager Therapeutics gets new chief medical officer
Mereo BioPharma Group plc (MREO)
See More Headlines
Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$10 million
Book Value
$0.36 per share


Free Float
Market Cap
$413.77 million
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Denise Vera Scots-Knight Ph.D. (Age 65)
    Co-Founder, CEO & Executive Director
    Comp: $890.56k
  • Mr. Charles Edward Sermon (Age 55)
    Co-Founder, General Counsel, Business Development & Company Secretary
    Comp: $625.79k
  • Ms. Christine Fox CPA (Age 43)
    Chief Financial Officer
    Comp: $569.77k
  • Dr. John P. Richard M.B.A. (Age 67)
    Co-Founder & Chief Business Officer
  • Dr. John A. Lewicki Ph.D. (Age 72)
    Chief Scientific Officer
  • Dr. Jackie Parkin (Age 66)
    Senior VP & Therapeutic Head
  • Ms. Alexandra Hughes-Wilson (Age 53)
    Chief of Patient Access & Commercial Planning
  • Dr. Suba Krishnan (Age 59)
    Senior Vice President of Clinical Development
  • Mr. Bo Kara
    Senior VP and Head of Pharmaceutical Development & CMC

MREO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mereo BioPharma Group stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MREO shares.
View MREO analyst ratings
or view top-rated stocks.

What is Mereo BioPharma Group's stock price target for 2024?

2 analysts have issued 1 year target prices for Mereo BioPharma Group's stock. Their MREO share price targets range from $6.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 101.2% from the stock's current price.
View analysts price targets for MREO
or view top-rated stocks among Wall Street analysts.

How have MREO shares performed in 2024?

Mereo BioPharma Group's stock was trading at $2.31 at the beginning of 2024. Since then, MREO stock has increased by 39.8% and is now trading at $3.23.
View the best growth stocks for 2024 here

Are investors shorting Mereo BioPharma Group?

Mereo BioPharma Group saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,210,000 shares, a drop of 21.9% from the April 30th total of 2,830,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is currently 2.2 days.
View Mereo BioPharma Group's Short Interest

When is Mereo BioPharma Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our MREO earnings forecast

How were Mereo BioPharma Group's earnings last quarter?

Mereo BioPharma Group plc (NASDAQ:MREO) announced its quarterly earnings results on Thursday, September, 7th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02).

What ETFs hold Mereo BioPharma Group's stock?

ETFs with the largest weight of Mereo BioPharma Group (NASDAQ:MREO) stock in their portfolio include Tema Oncology ETF (CANC) and Tema Cardiovascular and Metabolics ETF (HRTS).

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?

Mereo BioPharma Group (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (3.65%), Price T Rowe Associates Inc. MD (0.71%), Monaco Asset Management SAM (0.32%), Knoll Capital Management LLC (0.19%), Index Fund Advisors Inc. (0.02%) and BNP Paribas Financial Markets (0.01%).
View institutional ownership trends

How do I buy shares of Mereo BioPharma Group?

Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MREO) was last updated on 5/28/2024 by Staff

From Our Partners